Celularity Inc. (CELU)

3,0200 -0,0500 (-1,63%) Alla chiusura: 04:00PM EDT

Celularity Inc.

170 Park Avenue
Florham Park, NJ 07932
United States
908 768 2170
https://www.celularity.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 225

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Robert Joseph Hariri M.D., Ph.D.	Founder, CEO & Chairman	1,24M	N/D	1959
Mr. David C. Beers C.F.A.	Chief Financial Officer	455,02k	N/D	1970
Mr. John R. Haines	Senior EVP, Global Manager & Chief Administrative Officer	503,56k	N/D	1958
Ramji Krishnan	Chief Technology Officer	N/D	N/D	N/D
Carlos Ramirez	SVP of Investor Relations	N/D	N/D	N/D
Mr. Kyle Harold Fletcher Esq.	Executive VP, General Counsel & Chief Compliance Officer	N/D	N/D	1985
Dr. Stephen A. Brigido D.P.M.	President of Degenerative Diseases	N/D	N/D	1976
Dr. Adrian Kilcoyne M.B.A., M.D., M.P.H.	Executive VP, Chief Medical Officer and Head of Global Affairs, Patient Safety & Patient Affairs	N/D	N/D	1971
Sharmila Koppisetti M.D.	Senior Vice President of Clinical Dev. Immunology & Drug Safety	N/D	N/D	N/D
Mr. Tim Wilk	Senior Vice President of Technical Operations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Celularity Inc. al 1 aprile 2024 è 10. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 10; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.